Care Bears' first wellness brand plans gummy vitamins for kids and adults. Launch is targeted for first-half 2027.

Prenetics (NASDAQ: PRE) and Authentic Brands Group have partnered to launch Care Bears by IM8, a wellness brand offering gummy multivitamins for kids and adults, targeting a 2027 launch. Prenetics will record all revenue and pay royalties to Authentic. The global gummy supplements market is projected to reach $47.8 billion by 2030.

Original reporting
Published Nov 5, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 1:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$PRE
Bullish
high confidence
Mentioned
$PRE
Relevance
5/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$PREBullishLow
01

Why it matters

The announcement creates a new revenue source and aligns a strategic shareholder, likely prompting a modest share price rally.

02

Market read

First‑time disclosure of a multi‑year licensing deal that could expand Prenetics' addressable market and drive share price appreciation.

03

What to watch

Royalty payments to Authentic and execution risk of retail rollout could limit profitability.

Relevance 5/10Novelty 6/10Timing: announcement today

Background

Prenetics (NASDAQ: PRE) is a consumer health company known for its IM8 supplement line. Authentic Brands Group acquired the Care Bears IP in 2026.

Company-level read

Ticker impact

$PREBullishHigh confidence
Context

Prenetics announced a 10‑year exclusive partnership with Authentic Brands Group and that Authentic will become a strategic shareholder in Prenetics.

Expected impact

potential upside as the market prices in incremental growth from the Care Bears brand.

Evidence & confidence

First‑time disclosure of a multi‑year licensing partnership and equity stake, with no prior coverage.

Market effects

Adds a new consumer‑health brand to Prenetics' portfolio, potentially raising the outlook for the broader wellness supplement sector.

U.S. investors may view the partnership as a growth catalyst for a Nasdaq‑listed health‑tech company.

The Care Bears IP brings worldwide brand awareness, which could influence global retail and supplement markets.

Counterpoint

The partnership may dilute focus on Prenetics' core IM8 brand and the revenue upside is uncertain until launch in 2027.

Key entities

  • Prenetics Global Limited

    NASDAQ‑listed consumer health firm launching the Care Bears wellness brand.

  • Authentic Brands Group

    Owner of the Care Bears IP and new strategic shareholder in Prenetics.

Related articles

$PREMedAI 8/10

Prenetics Global reports Q3 results

Prenetics Global reported a Q3 net loss of $25.4M but revenue grew 171.6% year-over-year to $64.1M, exceeding estimates by $0.89M. The company's cash and current financial assets increased to $111.5M by September 30, 2026, up from $109.4M three months earlier.

$PREMed

Prenetics Global Ltd (PRE): Financial results for FY2027

Prenetics Global Ltd (PRE) furnished an SEC Form 6-K — earnings release. EX 99.1 Prenetics’ IM8 Reports Q3 2026 Revenue Growth of 266% YoY; Earliest Customers Have Returned More Than 3x Their Acquisition Cost in Under Two Years; Reaffirms FY 2026 Total Revenue Guidance of $220–230 Million and FY 2027 IM8 Revenue Guidance of $400 Million+ — Total reven

$PREMed

Prenetics Global Ltd (PRE): Financial results for Q2 2026

Prenetics Global Ltd (PRE) furnished an SEC Form 6-K — earnings release. Prenetics’ IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results Cumulative Personal Investment by Leadership Since November 2025 Reaches Approximately $3.75 Million NEW YORK, N.Y. – Aug. 26, 2026 (GLOBE NEWSWIRE) – Prenetics Global L

$PREMed

Prenetics (PRE) Q2 2026 Earnings Call Transcript

Prenetics (PRE) reported Q2 2026 revenue of $46.5M, up 29% from Q1 and 3.9x from a year ago, with IM8 contributing $45M. The company raised its full-year revenue guidance to $220M-$230M and initiated 2027 guidance of $400M+. July saw record revenue of $20.9M and a 21% drop in customer acquisition cost. PRE expects Q3 to be its first positive cash flow quarter and plans to launch new products in Q4 and Q1 2027.

$PREMed

Prenetics Global Q2 Earnings Call Highlights

Prenetics (NASDAQ:PRE) reported preliminary July revenue of $21.4M, including about $20.9M from IM8, and said it reached its highest monthly level. Q2 added 118,000 new IM8 customers (140,000 active subscribers). Q2 gross profit was $30.2M (65% margin); adjusted EBITDA loss was $19M. It expects H2 2026 adjusted EBITDA loss of $8M to $12M and a first positive quarter on an adjusted free-cash-flow basis with a $1B General Catalyst facility.